NCT00675012已完成2 期
NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
AGC Biologics S.p.A.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.
研究概览
简要总结
The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments
详细描述
Phase II, open-label, non-randomized study that will be conducted in two sequential cohorts of patients. Patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments are planned to be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years with metastatic colorectal cancer (CRC) treated with no more than three standard systemic regimens (including biologic agents) for metastatic disease
- •Life expectancy more than 3 months
- •ECOG Performance status 0-1
- •Adequate baseline bone marrow, hepatic and renal function, defined as follows:
- •Neutrophils >1.5 x 10^9/L and platelets > 100 x 10^9/L
- •Bilirubin <1.5 x ULN
- •AST and/or ALT <2.5 x ULN in absence of liver metastasis
- •AST and/or ALT <5 x ULN in presence of liver metastasis
- •Serum creatinine <1.5 x ULN
- •Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min
- •Patients may have had prior therapy providing the following conditions are met:
- •Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days before start treatment
- •Surgery: wash-out period of 14 days before start treatment
- •Patients must give written informed consent to participate in the study
排除标准
- •Concurrent anticancer therapy
- •Patients must not receive any other investigational agents while on study
- •Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
- •Uncontrolled hypertension
- •Prolonged QTc interval (congenital or acquired)
- •Patient with significant peripheral vascular disease
- •Clinical signs of CNS involvement
- •Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
- •Symptomatic peripheral neuropathy ≥ grade 1 according the NCI CTCAE v.3.
- •Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients
- •Known hypersensitivity/allergic reaction or contraindications to platinum compounds or fluoropyrimidines
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
- •Pregnancy or lactation.
- •Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study.
- •Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration
研究组 & 干预措施
A
Experimental
干预措施: NGR-hTNF (Drug)
A
Experimental
干预措施: Oxaliplatin (Drug)
A
Experimental
干预措施: capecitabine (Drug)
结局指标
主要结局
To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.
时间窗: during the study
次要结局
- Document the preliminary antitumor activity in terms of objective response rate (according to RECIST criteria) and progression-free survival(during the study)
- Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII(before during and following the treatment)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
?NGR005: Pilot study of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin-based regimen in patients wit metastatic colorectal cancer? - NGR005Patients with metastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-003668-24-ITMOLMED
已完成
1 期
A Modified Phase I Study of NGR-hTNF in Advanced Solid TumorsAdvanced Solid TumorsNCT00419328AGC Biologics S.p.A.16
已完成
1 期
Study of NGR-hTNF in Combination With Cisplatin in Solid TumorSolid TumorsNCT00483093AGC Biologics S.p.A.22
已完成
3 期
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With PemetrexedMalignant Pleural MesotheliomaNCT01098266AGC Biologics S.p.A.400
已完成
1 期
Study of NGR-hTNF in Combination With Doxorubicin in Solid TumorsCancerNCT00305084AGC Biologics S.p.A.15